KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) EBT Margin (2016 - 2025)

Historic EBT Margin for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Q4 2025 value amounting to 7.86%.

  • Alnylam Pharmaceuticals' EBT Margin rose 405600.0% to 7.86% in Q4 2025 from the same period last year, while for Dec 2025 it was 9.13%, marking a year-over-year increase of 259100.0%. This contributed to the annual value of 8.7% for FY2025, which is 254900.0% up from last year.
  • According to the latest figures from Q4 2025, Alnylam Pharmaceuticals' EBT Margin is 7.86%, which was up 405600.0% from 19.13% recorded in Q3 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' EBT Margin ranged from a high of 20.08% in Q3 2023 and a low of 153.59% during Q3 2022
  • Its 5-year average for EBT Margin is 53.13%, with a median of 43.34% in 2023.
  • Per our database at Business Quant, Alnylam Pharmaceuticals' EBT Margin crashed by -447400bps in 2022 and then skyrocketed by 1736700bps in 2023.
  • Alnylam Pharmaceuticals' EBT Margin (Quarter) stood at 100.68% in 2021, then surged by 39bps to 61.79% in 2022, then surged by 49bps to 31.31% in 2023, then decreased by -4bps to 32.7% in 2024, then surged by 124bps to 7.86% in 2025.
  • Its last three reported values are 7.86% in Q4 2025, 19.13% for Q3 2025, and 4.57% during Q2 2025.